MX2015012879A - Formulaciones combinadas de neosaxitoxina para una anestesia local prolongada. - Google Patents

Formulaciones combinadas de neosaxitoxina para una anestesia local prolongada.

Info

Publication number
MX2015012879A
MX2015012879A MX2015012879A MX2015012879A MX2015012879A MX 2015012879 A MX2015012879 A MX 2015012879A MX 2015012879 A MX2015012879 A MX 2015012879A MX 2015012879 A MX2015012879 A MX 2015012879A MX 2015012879 A MX2015012879 A MX 2015012879A
Authority
MX
Mexico
Prior art keywords
neostx
bupivacaine
combination
epinephrine
blockade
Prior art date
Application number
MX2015012879A
Other languages
English (en)
Inventor
Charles Berde
Daniel S Kohane
Original Assignee
Childrens Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50549480&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2015012879(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Childrens Medical Center filed Critical Childrens Medical Center
Publication of MX2015012879A publication Critical patent/MX2015012879A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A61K31/245—Amino benzoic acid types, e.g. procaine, novocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Anesthesiology (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicinal Preparation (AREA)

Abstract

Debido a que los bloqueadores de los canales de sodio que actúan sobre el sitio 1 presentan una actividad única y no pueden usarse para extrapolar la dosis eficaz de otros bloqueadores de los canales de sodio que actúan sobre el sitio 1, se realizaron estudios para identificar las dosis de la neosaxitoxina ("NeoSTX") y de la bupivacaina, por sí sola o en combinación con epinefrina, que podrían resultar eficaces para aliviar el dolor durante un período de dos ó tres días en los seres humanos. Las combinaciones de bupivacaina y NeoSTX provocaron un bloqueo con una confiabilidad y una duración mayores que las que se observaron cuando se administró la NeoSTX sola. Con una combinación de tres compuestos, NeoSTX, bupivacaína y epinefrina, se obtuvo una anestesia local más prolongada que la que se obtuvo con una combinación de dos compuestos, NeoSTX y bupivacaína. La adición de epinefrina a la combinación de NeoSTX y bupivacaína tuvo como consecuencia una prolongación dramática en la duración del bloqueo completo ante los estímulos mecánicos. Sobre la base de estos resultados, se desarrollaron diversas formulaciones de dosificación combinadas específicas.
MX2015012879A 2013-03-15 2014-03-17 Formulaciones combinadas de neosaxitoxina para una anestesia local prolongada. MX2015012879A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361789054P 2013-03-15 2013-03-15
PCT/US2014/030372 WO2014145580A1 (en) 2013-03-15 2014-03-17 Neosaxitoxin combination formulations for prolonged local anesthesia

Publications (1)

Publication Number Publication Date
MX2015012879A true MX2015012879A (es) 2016-06-24

Family

ID=50549480

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015012879A MX2015012879A (es) 2013-03-15 2014-03-17 Formulaciones combinadas de neosaxitoxina para una anestesia local prolongada.

Country Status (26)

Country Link
US (4) US10314833B2 (es)
EP (2) EP3492075B1 (es)
JP (1) JP6313420B2 (es)
KR (4) KR20210062693A (es)
CN (1) CN105142625B (es)
AU (2) AU2014232881B2 (es)
CA (2) CA3018668C (es)
CL (1) CL2015002534A1 (es)
CY (1) CY1121606T1 (es)
DK (1) DK2968225T3 (es)
ES (1) ES2727292T3 (es)
HK (1) HK1218384A1 (es)
HR (1) HRP20190419T1 (es)
HU (1) HUE042711T2 (es)
IL (1) IL241346B (es)
LT (1) LT2968225T (es)
MX (1) MX2015012879A (es)
NZ (1) NZ710890A (es)
PE (1) PE20160011A1 (es)
PL (2) PL3492075T3 (es)
PT (1) PT2968225T (es)
RS (1) RS58750B1 (es)
RU (2) RU2015143665A (es)
SI (1) SI2968225T1 (es)
TR (1) TR201903411T4 (es)
WO (1) WO2014145580A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014232881B2 (en) * 2013-03-15 2017-04-27 The Children's Medical Center Corporation Neosaxitoxin combination formulations for prolonged local anesthesia
US20170368176A1 (en) 2014-12-15 2017-12-28 The Children's Medical Center Corporation Non-toxic topical anesthetic ophthalmic compositions
US11344498B2 (en) 2015-10-08 2022-05-31 The Children's Medical Center Corporation Compositions and methods for on-demand high-efficiency triggerable anesthesia
US10117847B2 (en) 2015-12-04 2018-11-06 Ventis Pharma Extended duration local anesthetic formulation
US10791651B2 (en) 2016-05-31 2020-09-29 Carbice Corporation Carbon nanotube-based thermal interface materials and methods of making and using thereof
WO2019109065A1 (en) * 2017-12-01 2019-06-06 The Children's Medical Center Corporation Covalent anesthetic-polymer conjugates for prolonged local anesthesia
RU2701571C1 (ru) * 2019-02-13 2019-09-30 Федеральное государственное бюджетное образовательное учреждение высшего образования "Казанский Государственный медицинский университет" Министерства здравоохранения Российской Федерации Способ профилактики болевого синдрома после вмешательств на коленном суставе
US20230052318A1 (en) * 2020-01-06 2023-02-16 Pacira Pharmaceuticals, Inc. Treatment of pain associated with cesarean section surgery with sustained-release liposomal anesthetic compositions
CN115515581A (zh) 2020-01-10 2022-12-23 帕西拉制药股份有限公司 通过给予缓释脂质体麻醉组合物治疗疼痛
CN115297854A (zh) 2020-01-10 2022-11-04 帕西拉制药股份有限公司 通过蛛网膜下腔给予缓释脂质体麻醉组合物治疗疼痛
EP4274573A1 (en) 2021-01-11 2023-11-15 Pacira Pharmaceuticals, Inc. Treatment of hip pain with sustained-release liposomal anesthetic compositions
US11931459B2 (en) 2021-03-19 2024-03-19 Pacira Pharmaceuticals, Inc. Treatment of pain in pediatric patients by administration of sustained-release liposomal anesthetic compositions
US11918565B1 (en) 2022-11-03 2024-03-05 Pacira Pharmaceuticals, Inc. Treatment of post-operative pain via sciatic nerve block with sustained-release liposomal anesthetic compositions
US11977085B1 (en) 2023-09-05 2024-05-07 Elan Ehrlich Date rape drug detection device and method of using same

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3004894A (en) 1959-04-07 1961-10-17 Upjohn Co Therapeutic composition comprising tetracycline and a dioxolane
US3328259A (en) 1964-01-08 1967-06-27 Parachem Corp Dressing for a wound containing a hemostatic agent and method of treating a wound
US3374144A (en) 1965-10-07 1968-03-19 Miles Lab Ophthalmic composition
SE391286B (sv) 1971-01-26 1977-02-14 Astra Pharma Prod Forfarande for framstellning av en lokalanestetiskt verksam injektionslosning med forlengd varaktighet av verkan
US3966934A (en) 1971-12-08 1976-06-29 Astra Pharmaceutical Products, Inc. Synergistic local anesthetic compositions
US3957996A (en) 1971-12-08 1976-05-18 Astra Pharmaceutical Products, Inc. Pharmaceutical local anesthetic compositions
US4029794A (en) 1973-06-12 1977-06-14 Astra Pharmaceutical Products, Inc. Pharmaceutical local anesthetic composition
US4029793A (en) 1973-06-12 1977-06-14 Astra Pharmaceutical Products, Inc. Synergistic local anesthetic compositions
US4022899A (en) 1973-06-12 1977-05-10 Astra Pharmaceutical Products, Inc. Synergistic local anesthetic compositions
US4001413A (en) 1973-06-12 1977-01-04 Astra Pharmaceutical Products, Inc. Pharmaceutical local anesthetic composition employing saxitoxin
CA1165240A (en) 1980-07-09 1984-04-10 The Procter & Gamble Company Penetrating topical pharmaceutical compositions
US4313958A (en) 1980-10-24 1982-02-02 The Procter & Gamble Company Method of producing analgesia
US4460602A (en) 1981-06-30 1984-07-17 The Procter & Gamble Company Urea derivatives
US4401663A (en) 1981-06-30 1983-08-30 The Procter & Gamble Company Novel sulfonamide derivatives
US4443473A (en) 1981-06-30 1984-04-17 The Procter & Gamble Company Carbamate derivatives
US4537776A (en) 1983-06-21 1985-08-27 The Procter & Gamble Company Penetrating topical pharmaceutical compositions containing N-(2-hydroxyethyl) pyrrolidone
US4564633A (en) 1983-07-14 1986-01-14 The Procter & Gamble Company Compositions and methods useful for producing analgesia
US4544669A (en) 1983-07-14 1985-10-01 The Procter & Gamble Company Compounds and compositions useful for producing analgesia
US4544668A (en) 1983-07-14 1985-10-01 The Procter & Gamble Company Compounds and compositions useful for producing analgesia
US4493848A (en) 1983-07-14 1985-01-15 The Procter & Gamble Company Compositions and methods useful for producing analgesia
US4605670A (en) 1984-02-01 1986-08-12 Nitto Electric Industrial Co., Ltd. Method for percutaneously administering metoclopramide
CA1274508A (en) 1984-05-31 1990-09-25 Imre Szilagyi Primycin components and process for the separation of the antibiotic complex
US4654323A (en) 1984-11-13 1987-03-31 Bar Ilan University Method and composition for the therapeutic and prophylactic treatment of trauma to the skin
US5013759A (en) 1985-06-10 1991-05-07 The Procter & Gamble Company Compounds and compositions having anti-inflammatory and analgesic activity
US4863970A (en) 1986-11-14 1989-09-05 Theratech, Inc. Penetration enhancement with binary system of oleic acid, oleins, and oleyl alcohol with lower alcohols
US5006342A (en) 1986-12-22 1991-04-09 Cygnus Corporation Resilient transdermal drug delivery device
US5045565A (en) 1987-03-09 1991-09-03 The Procter & Gamble Company Novel compounds, pharmaceutical compositions, and methods for treating inflammation and pain
US5099030A (en) 1987-03-09 1992-03-24 The Procter & Gamble Company Novel compounds, pharmaceutical compositions, and methods for treating inflammation and pain
US4820720A (en) 1987-08-24 1989-04-11 Alza Corporation Transdermal drug composition with dual permeation enhancers
US5871472A (en) 1987-11-17 1999-02-16 Brown University Research Foundation Planting devices for the focal release of neuroinhibitory compounds
US5008289A (en) 1988-12-02 1991-04-16 Galenpharma, Inc. Composition for treating nasal disorders and headaches
US5134166A (en) 1988-12-02 1992-07-28 Genderm Corporation Method for treating nasal disorders and headaches
US4997853A (en) 1988-12-02 1991-03-05 Galenpharma, Inc. Method and compositions utilizing capsaicin as an external analgesic
US4973468A (en) 1989-03-22 1990-11-27 Cygnus Research Corporation Skin permeation enhancer compositions
WO1993011798A1 (en) 1991-12-16 1993-06-24 Alza Corporation Improved formulations with hydrophobic permeation enhancers
US5700485A (en) 1992-09-10 1997-12-23 Children's Medical Center Corporation Prolonged nerve blockade by the combination of local anesthetic and glucocorticoid
EP1132080A3 (en) 1992-09-10 2001-10-17 Children's Medical Center Corporation Biodegradable polymer matrices for sustained delivery of local anesthetic agents
US5576016A (en) 1993-05-18 1996-11-19 Pharmos Corporation Solid fat nanoemulsions as drug delivery vehicles
WO1995024903A1 (fr) 1994-03-17 1995-09-21 Nanning Maple Leaf Pharmaceutical Co., Ltd. Application de composes de quinazoline amino-hydrogenes et de leurs derives au sevrage des toxicomanes
EP0778768B1 (en) 1995-06-09 2004-05-26 Euroceltique S.A. Formulations and methods for providing prolonged local anesthesia
US5858397A (en) 1995-10-11 1999-01-12 University Of British Columbia Liposomal formulations of mitoxantrone
AU6883798A (en) 1997-04-02 1998-10-22 Regents Of The University Of California, The Method of anesthesia
AU7389098A (en) * 1997-05-16 1998-12-08 Brigham And Women's Hospital Local anesthetic formulations
US7016870B1 (en) 1997-12-02 2006-03-21 Financial Engines Identifying a recommended portfolio of financial products for an investor based upon financial products that are available to the investor
AU5286901A (en) 1999-10-22 2001-06-18 Transdermatech, Inc. Topical anesthetic formulation
US6673363B2 (en) 1999-12-16 2004-01-06 Dermatrends, Inc. Transdermal and topical administration of local anesthetic agents using basic enhancers
US6455066B1 (en) 2000-03-10 2002-09-24 Epicept Corporation Intradermal-penetration agents for topical local anesthetic administration
CN1284536C (zh) 2000-09-18 2006-11-15 威克斯医药有限公司 河豚毒素或蛤蚌毒素及其类似物在制备用于全身镇痛的镇痛药中的应用
CN1236773C (zh) 2000-11-22 2006-01-18 南宁枫叶药业有限公司 用于镇痛、麻醉或治疗药物依赖性的制剂
WO2002058670A1 (en) * 2001-01-25 2002-08-01 Euroceltique S.A. Local anesthetic, and method of use
CN1382443A (zh) 2001-04-25 2002-12-04 威克斯医疗仪器有限公司 钠离子通道阻断剂在制备用于局部神经麻醉或镇痛的药物中的应用
EP1443932B1 (en) * 2001-11-15 2012-12-26 Micro Algae Corporation Pharmaceutical compositions containing 3,4-propinoperhydropurines and uses thereof for blocking neuronal transmission
US20050202093A1 (en) 2002-12-02 2005-09-15 Kohane Daniel S. Prolonged suppression of electrical activity in excitable tissues
US20040172354A1 (en) 2003-02-13 2004-09-02 Charnley James Allen Calculator for illustrating investment performance for irregular time periods
WO2005079157A2 (en) 2004-02-19 2005-09-01 Dmitry Gorbatovsky Portfolio optimization
US20050214325A1 (en) 2004-03-26 2005-09-29 Vvii Newco 2003, Inc. Compositions and methods to increase the effect of a neurotoxin treatment
US8377951B2 (en) 2004-05-07 2013-02-19 Phytotox Limited Transdermal administration of phycotoxins
CN100367966C (zh) 2004-09-28 2008-02-13 黄致强 河鲀毒素油相制剂的制备方法
WO2006091719A2 (en) 2005-02-23 2006-08-31 Sontra Medical Corporation Compositions and methods enhancing transdermal delivery of drugs and biologics
DK2101819T3 (da) 2006-11-20 2013-04-29 Harvard College Fremgangsmåder, sammensætninger og kits til behandling af smerte og pruritis
WO2009143175A2 (en) 2008-05-19 2009-11-26 Children's Medical Center Corporation Sensory-specific local anesthesia and prolonged duration local anesthesia
US8658699B2 (en) 2008-05-19 2014-02-25 Massachusetts Institute Of Technology Chemical permeation enhancers enhance nerve blockade by toxins
KR20120081938A (ko) 2008-10-07 2012-07-20 이섬 리서치 디벨러프먼트 컴파니 오브 더 히브루 유니버시티 오브 예루살렘 엘티디. 스핑고마이엘린을 포함하는 리포좀 시스템
CL2009000723A1 (es) 2009-03-24 2009-06-19 Proteus Sa Metodo de purificacion industrial de ficotoxinas biologicamente activas que comprende proporcionar una cantidad adecuada de una fuente de ficotoxinas como por ejemplo el cultivo de un clon de cianobacterias.
CL2009000722A1 (es) 2009-03-24 2009-06-19 Proteus Sa Metodo de obtención y producción masiva de una especie de cianobacteria aislada productora de ficotoxinas paralizantes, utilizando un medio de cultivo mla suplementado con arginina, metionina y ácido alantoico.
WO2010117996A1 (en) 2009-04-08 2010-10-14 Children's Medical Center Corporation Prolonged duration local anesthesia with minimal toxicity
US9174999B2 (en) 2009-05-07 2015-11-03 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for studying, imaging, and treating pain
ES2484315T3 (es) * 2010-02-10 2014-08-11 Phytotox Limited Tratamiento de la pérdida del sentido del tacto con derivados de saxitoxina
AU2014232881B2 (en) * 2013-03-15 2017-04-27 The Children's Medical Center Corporation Neosaxitoxin combination formulations for prolonged local anesthesia

Also Published As

Publication number Publication date
DK2968225T3 (da) 2019-05-27
CA3018668C (en) 2021-04-13
CA2906851A1 (en) 2014-09-18
AU2017202343B2 (en) 2019-02-07
US20140288103A1 (en) 2014-09-25
KR20220132666A (ko) 2022-09-30
US20140329861A1 (en) 2014-11-06
PL2968225T3 (pl) 2019-08-30
CL2015002534A1 (es) 2016-09-16
CN105142625B (zh) 2019-09-06
HRP20190419T1 (hr) 2019-05-03
AU2017202343A1 (en) 2017-04-27
RU2015143665A (ru) 2017-04-27
ES2727292T3 (es) 2019-10-15
EP2968225B1 (en) 2019-02-20
US20190247377A1 (en) 2019-08-15
KR20150131330A (ko) 2015-11-24
BR112015021380A2 (pt) 2018-05-08
HUE042711T2 (hu) 2019-07-29
KR20240042210A (ko) 2024-04-01
CN105142625A (zh) 2015-12-09
HK1218384A1 (zh) 2017-02-17
CY1121606T1 (el) 2020-05-29
TR201903411T4 (tr) 2019-04-22
US20140329841A1 (en) 2014-11-06
IL241346B (en) 2018-07-31
AU2014232881A1 (en) 2015-08-27
EP3492075B1 (en) 2023-12-13
RU2673081C1 (ru) 2018-11-22
JP2016514704A (ja) 2016-05-23
IL241346A0 (en) 2015-11-30
US10881647B2 (en) 2021-01-05
PE20160011A1 (es) 2016-02-10
RS58750B1 (sr) 2019-06-28
AU2014232881B2 (en) 2017-04-27
US10314833B2 (en) 2019-06-11
SI2968225T1 (sl) 2019-05-31
CA2906851C (en) 2019-05-07
EP2968225A1 (en) 2016-01-20
LT2968225T (lt) 2019-04-25
US8975281B2 (en) 2015-03-10
JP6313420B2 (ja) 2018-04-18
PT2968225T (pt) 2019-04-02
WO2014145580A1 (en) 2014-09-18
US8975268B2 (en) 2015-03-10
KR20210062693A (ko) 2021-05-31
PL3492075T3 (pl) 2024-04-22
CA3018668A1 (en) 2014-09-18
EP3492075A1 (en) 2019-06-05
NZ710890A (en) 2016-11-25

Similar Documents

Publication Publication Date Title
MX2015012879A (es) Formulaciones combinadas de neosaxitoxina para una anestesia local prolongada.
CR20160170A (es) Moduladores del factor del complemento b
MX2015016983A (es) Moduladores del transporte nuclear y usos de los mismos.
BR112014016805A2 (pt) compostos terapeuticamente ativos e seus métodos de uso
UA122324C2 (uk) Терапевтично активні сполуки і способи їх застосування
BR112016009889A2 (pt) ?compostos agonistas duplos gip-glp-1 e métodos?
TR201902516T4 (tr) Glukagon-glp-1-gıp üçlü agonist bileşikleri.
MY179696A (en) Compositions and methods comprising bupropion or related compounds and dextromethorphan
BR112015020466A8 (pt) inibidores de cdc7, seus usos, e composição farmacêutica
BR112016002287A2 (pt) compostos terapeuticamente ativos e seus métodos de uso
BR112016000561A8 (pt) compostos terapeuticamente ativos e seus métodos de uso
BR112015027281A2 (pt) combinações de dosagens para reduzir respostas imunológicas humorais indesejadas
BR112012027197A2 (pt) combinação ou composição farmacêutica, seu uso, kit, e compostos para tratamento de doenças oncológicas e fibróticas
EA201591987A1 (ru) Лечение злокачественной опухоли дигидропиразинопиразинами
MX2015016100A (es) Inhibidores de criopirina para prevenir y tratar la inflamacion.
BR112015026247A2 (pt) métodos para o tratamento de câncer com o uso de terapia combinada com inibidor de cinase tor
BR112015017241A2 (pt) doadores de nitroxil com índice terapêutico melhorado
BR112015010039A2 (pt) tratamento de câncer com pomalidomida em um individuo com disfunção renal
NI201600070A (es) Inhibidores tetracíclicos de autotaxina
MX2021013354A (es) Metodos para tratar y/o prevenir queratosis actinica.
CL2009000660A1 (es) Uso de un antagonista del receptor 2 activado con proteasa (par2) para tratar, inhibir o aliviar el dolor.
EA201591450A1 (ru) Фармацевтический состав, содержащий гликозаминогликан
CL2008000090A1 (es) Compuestos derivados de piridina; composicion farmaceutica que comprende a dichos compuestos; y su uso como inhibidores del receptor p2y 12 para tratar un trastorno de agragacion de plaquetas.
AR106220A1 (es) Conjugados homogéneos específicos de sitio con inhibidores de ksp
AR096935A1 (es) Métodos de tratamiento de cáncer usando antagonistas de unión al eje pd-1 e inhibidores de tigit, kit